Pharmacokinetic Evaluation of Fosaprepitant Dimeglumine

Overview

Journal Expert Opin Drug Metab Toxicol

Publisher Informa Healthcare

Specialties Endocrinology
Pharmacology
Toxicology

Date 2010 Aug 28

PMID 20795794

Citations 15

Authors

Francheska Colon-Gonzalez

Walter K Kraft

Affiliations

Soon will be listed here.

Abstract

Importance Of The Field: Chemotherapy induced nausea and vomiting (CINV) is a common complication in the treatment of patients with cancer. The introduction of the first in class neurokinin-1 receptor antagonist aprepitant provided additive control on CINV in combination to existing antiemetics. Due to formulation issues, aprepitant is only available for oral administration. Fosaprepitant, a prodrug of aprepitant, was introduced to the market in 2008 as an intravenous bioequivalent to aprepitant.

Areas Covered In This Review: This review examines the chemical development of fosaprepitant, its pharmacokinetic properties, approved uses and potential applications.

What The Reader Will Gain: The reader will get up-to-date information on the pharmacology and clinical uses of fosaprepitant. Clinical studies have demonstrated pharmacokinetic bioequivalence of aprepitant 125 mg to fosaprepitant 115 mg, as well as comparable efficacy in prevention of acute and delayed emesis following the first day of chemotherapy regimens.

Take Home Message: Fosaprepitant is an intravenous prodrug of aprepitant that offers a new alternative to patients with CINV. Currently, fosaprepitant can substitute oral aprepitant in day 1 of a 3-day regimen. Current studies show that a single-day fosaprepitant regimen is also bioequivalent to the 3-day aprepitant regimen; this could significantly simplify the care for CINV patients in the future.

Citing Articles

[Update PO(N)V-What is new in the prophylaxis and treatment of postoperative nausea and vomiting?].

Knoth S, Weber B, Lotz H, Vojnar B, Eberhart L Anaesthesiologie. 2025; 74(3):171-186.

PMID: 40009227 DOI: 10.1007/s00101-025-01510-z.

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database.

Yang C, Xu P, Wu T, Fan Y, Li Q, Zhang J Front Pharmacol. 2024; 15:1413709.

PMID: 39144621 PMC: 11321956. DOI: 10.3389/fphar.2024.1413709.

Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.

Vink R, Nimmo A Int J Mol Sci. 2024; 25(6).

PMID: 38542509 PMC: 10970734. DOI: 10.3390/ijms25063535.

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis.

Xu X, Bao Y, Xu K, Zhang Z, Zhao N, Li X Front Public Health. 2022; 10:913129.

PMID: 35903377 PMC: 9315060. DOI: 10.3389/fpubh.2022.913129.

Discovery of Antibacterial Contezolid Acefosamil: Innovative -Acyl Phosphoramidate Prodrug for IV and Oral Therapies.

Liu J, Wang W, Wang C, Zhang L, Zhang X, Liu S ACS Med Chem Lett. 2022; 13(7):1030-1035.

PMID: 35859881 PMC: 9290071. DOI: 10.1021/acsmedchemlett.2c00191.

References

Jordan K, Sippel C, Schmoll H . Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007; 12(9):1143-50. DOI: 10.1634/theoncologist.12-9-1143. View

Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P . Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005; 61(5-6):341-6. DOI: 10.1007/s00228-005-0907-8. View

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

Munoz M, Rosso M . The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs. 2009; 28(2):187-93. DOI: 10.1007/s10637-009-9218-8. View

Kesisoglou F, Panmai S, Wu Y . Nanosizing--oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007; 59(7):631-44. DOI: 10.1016/j.addr.2007.05.003. View

Poli-Bigelli S, Rodrigues-Pereira J, Carides A, Ma G, Eldridge K, Hipple A . Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003; 97(12):3090-8. DOI: 10.1002/cncr.11433. View

Le T, Gan T . Update on the management of postoperative nausea and vomiting and postdischarge nausea and vomiting in ambulatory surgery. Anesthesiol Clin. 2010; 28(2):225-49. DOI: 10.1016/j.anclin.2010.02.003. View

Van Belle S, Lichinitser M, Navari R, Garin A, Decramer M, Riviere A . Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002; 94(11):3032-41. DOI: 10.1002/cncr.10516. View

Moore S, Tumeh J, Wojtanowski S, Flowers C . Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health. 2007; 10(1):23-31. DOI: 10.1111/j.1524-4733.2006.00141.x. View

10.

Prommer E . Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother. 2005; 19(3):31-9. View

11.

Hargreaves R . Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. 2003; 63 Suppl 11:18-24. View

12.

Roila F, Hesketh P, Herrstedt J . Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2005; 17(1):20-8. DOI: 10.1093/annonc/mdj078. View

13.

Junghanns J, Muller R . Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008; 3(3):295-309. PMC: 2626933. DOI: 10.2147/ijn.s595. View

14.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011; 29(11):1495-501. DOI: 10.1200/JCO.2010.31.7859. View

15.

Herrstedt J, Roila F . Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2009; 20 Suppl 4:156-8. DOI: 10.1093/annonc/mdp160. View

16.

Tattersall F, Rycroft W, Hargreaves R, Hill R . The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol. 1993; 250(1):R5-6. DOI: 10.1016/0014-2999(93)90649-3. View

17.

Roila F, Herrstedt J, Aapro M, Gralla R, Einhorn L, Ballatori E . Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21 Suppl 5:v232-43. DOI: 10.1093/annonc/mdq194. View

18.

Hale J, Mills S, MacCoss M, Dorn C, Finke P, Budhu R . Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem. 2000; 43(6):1234-41. DOI: 10.1021/jm990617v. View

19.

Hesketh P, Grunberg S, Herrstedt J, de Wit R, Gralla R, Carides A . Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006; 14(4):354-60. DOI: 10.1007/s00520-005-0914-4. View

20.

Warr D, Hesketh P, Gralla R, Muss H, Herrstedt J, Eisenberg P . Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23(12):2822-30. DOI: 10.1200/JCO.2005.09.050. View